Document is current
Any future updates will be listed below
-
Authors
Kanne, Julian
Hussong, Michelle
Isensee, Jörg http://orcid.org/0000-0002-3390-0051
Muñoz-López, Álvaro
Wolffgramm, Jan
Heß, Felix
Grimm, Christina http://orcid.org/0000-0002-4676-8870
Bessonov, Sergey
Meder, Lydia
Wang, Jie
Reinhardt, H. Christian
Odenthal, Margarete
Hucho, Tim
Büttner, Reinhard
Summerer, Daniel
Schweiger, Michal R. http://orcid.org/0000-0002-2139-3478
- License Information
-
More Information
Article History
Received: 17 October 2020
Revised: 4 March 2021
Accepted: 10 May 2021
First Online: 24 May 2021
Ethics statement
: PDX data in this study were derived from Grasse et al.<sup>22</sup>. The establishment of these PDX models from NSCLC patients was approved (EA3/001/06) by the local ethical review committee (Charité Berlin). Written informed consent to participate in the study was obtained from all patients. The use of clinical data and patient’s material was approved by the institutional review board of the ELK Berlin Chest Hospital. All mice used in the study were handled in accordance with the Guidelines for the Welfare and Use of Animals in Cancer Research<sup>53</sup>. Their use was approved by the local responsible authorities (approval no. G 0030/15), according to the German Animal Protection Law.
: H.C.R. received consulting and lecture fees from Abbvie, Astra-Zeneca, Vertex, and Merck. H.C.R. received research funding from Gilead Pharmaceuticals. H.C.R. is a co-founder of CDL Therapeutics GmbH. No potential conflicts of interest were disclosed by the other authors.
